These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 23661716)
1. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? Ou SH J Clin Pathol; 2013 Oct; 66(10):839-46. PubMed ID: 23661716 [TBL] [Abstract][Full Text] [Related]
2. Republished: lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? Ou SH Postgrad Med J; 2014 Apr; 90(1062):228-35. PubMed ID: 24643262 [TBL] [Abstract][Full Text] [Related]
3. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530 [TBL] [Abstract][Full Text] [Related]
4. Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. Viñolas N; Garrido P; Isla D; Provencio M; Majem M; Artal A; Carcereny E; Garcia Campelo R; Lianes P; De La Peñas R; Felip E Cancer Invest; 2017 May; 35(5):358-365. PubMed ID: 28350480 [TBL] [Abstract][Full Text] [Related]
5. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
6. Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations. Dacic S J Clin Pathol; 2013 Oct; 66(10):870-4. PubMed ID: 23801495 [TBL] [Abstract][Full Text] [Related]
7. Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations. Gaughan EM; Cryer SK; Yeap BY; Jackman DM; Costa DB Lung Cancer; 2013 Mar; 79(3):193-7. PubMed ID: 23273562 [TBL] [Abstract][Full Text] [Related]
8. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898 [TBL] [Abstract][Full Text] [Related]
9. Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature. Thumallapally N; Yu H; Farhan M; Ibrahim U; Odiami M J Pharm Pract; 2018 Apr; 31(2):244-248. PubMed ID: 28438075 [TBL] [Abstract][Full Text] [Related]
10. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China. Li X; Zhao C; Su C; Ren S; Chen X; Zhou C BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199 [TBL] [Abstract][Full Text] [Related]
11. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations. Xu L; Lei J; Wang QZ; Li J; Wu L Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450 [TBL] [Abstract][Full Text] [Related]
13. Different histopathology but the same clonality: ALK rearrangement in a patient with metastatic non-small-cell lung cancer. Zhao J; Zhou J; Chen Z; Wang B; Zhang X; Zhou J; Ding W Int J Clin Exp Pathol; 2015; 8(3):3344-8. PubMed ID: 26045865 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073 [TBL] [Abstract][Full Text] [Related]
15. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL Oncology; 2015; 89(3):175-86. PubMed ID: 25833149 [TBL] [Abstract][Full Text] [Related]
16. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma. Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151 [TBL] [Abstract][Full Text] [Related]
17. Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. Soo RA; Kubo A; Ando M; Kawaguchi T; Ahn MJ; Ou SI Clin Lung Cancer; 2017 Sep; 18(5):535-542. PubMed ID: 28433570 [TBL] [Abstract][Full Text] [Related]
18. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization. Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706 [TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463 [TBL] [Abstract][Full Text] [Related]
20. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]